This earnings season isn't shaping up to be a merry one for coronavirus stock Teladoc Health (NYSE: TDOC) following the release of its latest earnings after the market close Tuesday. For its second quarter, Teladoc managed to grow its top line by 109% to $503 million, fueled by 138% growth in the company's access fees (which accounted for 86% of total revenue). More than a little of this was due to expenses related to the large-scale acquisition of healthcare sector peer Livongo Health.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting